<div><div></div><div>Tango Therapeutics entered into an Underwriting Agreement with J.P. Morgan Securities and Leerink Partners for an underwritten offering of 18,166,667 common shares at $30.00 per share and pre-funded warrants for 1,833,395 shares at $29.999. The underwriters have a 30-day option to buy up to 3,000,009 additional shares. Net proceeds are estimated at approximately $566.5 million, with closing expected on June 11, 2026. The company plans to use the funds for R&amp;D, its pivotal trial, commercialization preparation, and general corporate purposes.Agreement details:<ul><li>Agreement type: Underwriting agreement for public offering of common stock and pre-funded warrants</li><li>Counterparty: J.P. Morgan Securities and Leerink Partners, as representatives of the underwriters</li><li>Signed / Effective: Jun 09 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Fund R&amp;D, pivotal trial, and commercialization prep</li></ul>Original SEC Filing: Tango Therapeutics, Inc. [ TNGX ] - 8-K - Jun. 10, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

TNGX

JPMO

Tango Therapeutics priced a $566.5 million equity offering at $30 per share, including pre-funded warrants. The company raised funds via an underwritten public offering with J.P. Morgan and Leerink Partners. Net proceeds will support R&D, pivotal trials, commercialization preparation, and general corporate purposes. A 30-day option allows underwriters to purchase up to 3 million additional shares. Closing is expected on June 11, 2026.

TradingView

Tango Therapeutics

JPMorgan Chase

YieldMax JPM Option Income Strategy ETF

Defiance Daily Target 2X Long JPM ETF

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted